Search

Displaying results 661 - 670 of 7536 in total
  1. Drug

    Chymopapain

    go.drugbank.com/drugs/DB06752
    ApprovedWithdrawn

    Chymopapain was first isolated in 1941 from the crude latex derived from the fruit of Carica papaya by squeezing the green papaya while on the plant prior to harvest. … [L2482]It is an extracellular plant cysteine proteinase similar to papain in specificity.[A32688] Chymopapain was developed by Chart Medcl and FDA approved on November 10, 1982.

  2. Drug

    Thermus thermophilus lysate

    go.drugbank.com/drugs/DB11227
    Approved

    Mixtures: Skin Doctors Photo Age Reverse, Skin Doctors Photo Age Reverse Night Serum
  3. Drug

    Elinzanetant

    go.drugbank.com/drugs/DB18968
    ApprovedInvestigational

    [A274198] On July 23, 2025, it was approved by Health Canada to treat moderate to severe vasomotor symptoms (VMS) associated with menopause. … [L53798] By blocking receptor signaling on kisspeptin/neurokinin B/dynorphin (KNDy) neurons, which are hyperactivated due to estrogen decline in menopause, elinzanetant modulates neuronal activity involved

    Synonyms: 2-(3,5-bis(trifluoromethyl)phenyl)-n-(4-(4-fluoro-2-methylphenyl)-6-((7s,9as)-7-(hydroxymethyl)hexahydropyrazino(2,1-c)(1,4)oxazin-8(1h)-yl)-3-pyridinyl)-n,2-dimethylpropanamide, Benzamide, 3-(5-methyl-2-tbenzeneacetamide, n-(4-(4-fluoro-2-methylphenyl)-6-((7s,9as)-hexahydro-7-(hydroxymethyl)pyrazino(2,1-c)(1,4)oxazin-8(1h)-yl)-3-pyridinyl)-n,.alpha.,.alpha.
  4. Drug

    Busulfan

    go.drugbank.com/drugs/DB01008
    ApprovedInvestigational

    It has been used in the palliative treatment of chronic myeloid leukemia (myeloid leukemia, chronic), but although symptomatic relief is provided, no permanent remission is brought about. … Busulfan is a bifunctional alkylating agent, having a selective immunosuppressive effect on bone marrow. It is not a structural analog of the nitrogen mustards.

  5. Drug

    Caplacizumab

    go.drugbank.com/drugs/DB06081
    ApprovedInvestigational

    Caplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019,[L5302] and approved previously by the EU in October 2018 as a combination therapy with plasma exchange and immunosuppression … [A174634]In December 2025, the FDA expanded this indication to include pediatric patients aged 12 years and older with aTTP, in the same combination regimen.[L54958,L54963]

  6. Drug

    Iopodic acid

    go.drugbank.com/drugs/DB09333
    ApprovedWithdrawn

    On September 22, 1981, ipodate was submitted again by the company Schering AG but it is currently under an inactive status.[L1082] … This drug was approved on March 15, 1962 but it is nowadays discontinued from the FDA and Health Canada.

  7. Drug

    Benzoic acid

    go.drugbank.com/drugs/DB03793
    ApprovedInvestigational

    Total Positive and Negative Syndrome Scale scores dropped by 21% compared to placebo. … As the sodium salt form, sodium benzoate is used as a treatment for urea cycle disorders due to its ability to bind amino acids.

    Mixtures: POLY-N OINTMENT, NEO BOROCILLINAProducts: Seo Jeong Ho Hwang Chill Mist, Seo Jeong Ho Hwang Chill Deodorant
  8. Drug

    Varenicline

    go.drugbank.com/drugs/DB01273
    ApprovedInvestigational

    Varenicline is a prescription medication used to treat smoking addiction. This medication is the first approved nicotinic receptor partial agonist. … In addition it acts on alpha3/beta4 and weakly on alpha3beta2 and alpha6-containing receptors. A full agonism was displayed on alpha7-receptors. On March 9, 2015, the U.S.

  9. Drug

    Doxepin

    go.drugbank.com/drugs/DB01142
    ApprovedInvestigational

    [T83] In a strict sense, doxepin is not a tricyclic antidepressant but it is commonly associated with the class since it shares a lot of properties with members of the drug family including [amitriptyline … The latter indication was presented by Pernix Therapeutics.[L5974]

    Categories: Non-Selective Monoamine Reuptake Inhibitors, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  10. Drug

    Netilmicin

    go.drugbank.com/drugs/DB00955
    Approved

    Netilmicin is a semisynthetic 1-N-ethyl derivative of sisomycin, an aminoglycoside antibiotic with action similar to gentamicin, but less ear and kidney toxicity. … Netilmicin inhibits protein synthesis in susceptible organisms by binding to the bacterial 30S ribosomal subunit and interfering with mRNA binding and the acceptor tRNA site.

    Synonyms: 1-N-Ethylsisomicin